ROSSINI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 603
EU - Europa 442
AS - Asia 120
AF - Africa 3
Totale 1.168
Nazione #
US - Stati Uniti d'America 603
RU - Federazione Russa 205
IT - Italia 67
IE - Irlanda 48
SE - Svezia 37
HK - Hong Kong 34
PL - Polonia 31
CN - Cina 30
SG - Singapore 25
JO - Giordania 19
DE - Germania 15
IN - India 9
CZ - Repubblica Ceca 7
GB - Regno Unito 7
FI - Finlandia 5
FR - Francia 5
CH - Svizzera 4
BE - Belgio 3
ES - Italia 3
NL - Olanda 3
DZ - Algeria 2
VN - Vietnam 2
BY - Bielorussia 1
CI - Costa d'Avorio 1
TH - Thailandia 1
UA - Ucraina 1
Totale 1.168
Città #
Santa Clara 149
Chandler 52
Fairfield 49
Dublin 47
Ashburn 38
Woodbridge 33
Ann Arbor 31
Warsaw 30
Houston 29
Hong Kong 28
Cambridge 24
Seattle 21
Singapore 21
Wilmington 20
Beijing 11
Florence 10
Lawrence 9
Mumbai 9
Altamura 8
Moscow 8
New York 8
Princeton 8
Brno 7
Shanghai 7
Medford 5
Milan 5
Rome 5
Yubileyny 5
Bern 4
Boardman 4
Boston 4
Buffalo 4
Helsinki 4
Modena 4
Munich 4
San Diego 4
Trevignano 4
Barcelona 3
Brussels 3
Esslingen am Neckar 3
Algiers 2
Amsterdam 2
Bari 2
Bologna 2
Dong Ket 2
Kent 2
Lurate Caccivio 2
Nepi 2
Norwalk 2
Paris 2
Parma 2
Redwood City 2
Rieti 2
Udine 2
Vicopisano 2
West Jordan 2
Abidjan 1
Bangkok 1
Busto Arsizio 1
Castel San Giovanni 1
Chicago 1
Frankfurt am Main 1
Hillsboro 1
London 1
Lublin 1
Nagold 1
Naples 1
Prescot 1
San Marco dei Cavoti 1
Saronno 1
Wuhan 1
Zhengzhou 1
Totale 770
Nome #
Liquid chromatographic/electrospray ionization quadrupole/time of flight tandem mass spectrometric study of polyphenolic composition of different Vaccinium berry species and their comparative evaluation 148
Processing of polymer-derived silicon carbide foams and their adsorption capacity for non-steroidal anti-inflammatory drugs 142
Determination of phthalate diesters and monoesters in human milk and infant formula by fat extraction, size-exclusion chromatography clean-up and gas chromatography-mass spectrometry detection 141
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 130
Applicability of the direct injection liquid chromatographic tandem mass spectrometric analytical approach to the sub-ng L-1 determination of perfluoro-alkyl acids in waste, surface, ground and drinking water samples 129
On-line SPE-LC-MS/MS analysis of wide-range polarity pharmaceutical compounds in aqueous matrices: problems and solutions 109
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 98
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 78
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 70
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 67
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 63
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 28
Totale 1.203
Categoria #
all - tutte 4.265
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.265


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202086 0 0 0 0 11 13 13 10 12 11 13 3
2020/2021108 10 6 7 10 2 9 7 8 13 28 3 5
2021/202256 11 2 0 4 1 4 2 2 0 8 5 17
2022/2023260 12 36 8 20 14 40 34 26 43 2 15 10
2023/2024122 7 10 12 8 10 10 6 35 4 9 8 3
2024/2025444 27 59 50 130 178 0 0 0 0 0 0 0
Totale 1.203